Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 30; p. ii77
Main Authors	Owonikoko, T.K., Kim, H.R., Govindan, R., Ready, N., Reck, M., Peters, S., Dakhil, S.R., Navarro, A., Rodriguez-Cid, J., Schenker, M., Lee, J.S., Gutierrez, V., Percent, I., Morgensztern, D., Fairchild, J., Baudelet, C., Park, K.
Format	Journal Article
Language	English
Published	England Elsevier Ltd 01.04.2019
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdz094